Assessment of efficacy of Botulinium toxin A for treatment of keloid

Comparison of efficacy of " Botulinium Toxin A plus Triamcinolone" intralesional injection with intralesional injection of Triamcinolone alone for treatment of keloid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014071918533N1

Enrollment

Registered

2014-08-11

Start date

2014-08-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

keloid scar. Hypertrophic scar

Interventions

Intervention 1: Triamcinolone intralesional injection 20mg/ml monthly for 3 months. Intervention 2: Triamcinolone intralesional injection 20mg/ml+Botulinum toxin A 20u/ml intralesional injection month

Treatment - Drugs

Triamcinolone intralesional injection 20mg/ml monthly for 3 months

Triamcinolone intralesional injection 20mg/ml+Botulinum toxin A 20u/ml intralesional injection monthly for 3months

Eligibility

Sex/Gender

All

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: ]nclusion criteria:patients should have at least too keloids on the skin ;age between 15 and 45 years Exclusion criteria:pregnant or breast feeding women ;neuromuscular jaunction diseases or receiving neuromuscular junction blocker agents

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Height of keloid. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Caliper in milimeters.;Consistency of keloid. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-5.;Vascularity. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-3.;Pigmentation. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-3.;Pain. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Subjective scale of pain:score 1-10.;Itch. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Subjective scale of itch:score 1-10.	—

Measure

Time frame

Height of keloid. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Caliper in milimeters.;Consistency of keloid. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-5.;Vascularity. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-3.;Pigmentation. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Physical examination score 1-3.;Pain. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Subjective scale of pain:score 1-10.;Itch. Timepoint: Before treatment ond 1 month after end of treatment. Method of measurement: Subjective scale of itch:score 1-10.

—

Secondary

Measure	Time frame
Skin atrophy. Timepoint: 1 month after end of treatment. Method of measurement: yes or no.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeiede Nasibe Sohrabian

Ahvaz Jundishapur University of Medical Sciences

sohrabian.n@ajums.ac.ir+98 64 1626 3722

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026